Cancer patients
Conditions
Interventions
1. Intake of study product
2. Duration of intervention: 8 days
3. Intervention group: cancer patients.
Sponsors
Danone Research ¨C Centre for Specialised Nutrition
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed solid tumor(s); 2. Body Mass Index 18.5 - 30 kg/ m2; 3. Willing and able to abstain from use of alcohol, smoking, fish (fatty fish e.g. salmon, mackerel, herring, eel), fish oil containing supplements and vitamin supplements or oil supplements (e.g. evening primrose oil); 4. Age ¡Ý 18 years; 5. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Surgery, radiotherapy, chemotherapy and or hormone therapy less than 2 months ago or planned within the study period; 2. Use of supplements containing fish oil, vitamins or oil supplements (e.g. evening primrose oil) during the previous 4 weeks; 3. Intolerance or allergy to dairy products, fish, or other ingredients of the study products; 4. Altered immune function (e.g. caused by major active infection, autoimmune disease, active allergy, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, or by use of medication such as immunosuppressive drugs, immunomodulators including NSAIDs, or corticosteroids (unless not considered to be systemically available) as listed in appendix I); 5. Currently smoking and smoking in the past 6 months; 6. Life expectancy 2; 8. Dependence on tube feed or parenteral nutrition in the last 4 weeks; 9. If pre-menopausal female: pregnant or lactating; 10. Dementia or altered mental status that would prohibit the understanding and giving of informed consent; 11. Any other medical condition that may interfere with the safety of the patient or the outcome parameters, in the investigator's judgement; 12. Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. alcohol abuse).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Incorporation kinetics of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in membrane phospholipids of white and red blood cells and plasma phospholipids; 2. Effects on ex vivo immune responses in cancer patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of nutritional supplementation on inflammatory status. | — |
Contacts
Public ContactW. Graaf de
ziekenhuisapotheek MCA, Postbus 501
Outcome results
None listed